BLCO Bausch + Lomb Corp

This article analyzes Bausch + Lomb's (NYSE:BLCO) current share price using discounted cash flow (DCF) and price-to-sales (P/S) ratio analyses, suggesting the stock may be undervalued. Despite recent positive sentiment and strategic shifts towards higher-margin eye health products, the stock has underperformed year-to-date. The analysis concludes that the market might be heavily discounting the company's future cash generation potential.

Bausch + Lomb Corporation announced that its Chairman and CEO Brent Saunders, Executive Vice President and CFO Sam Eldessouky, and Chief Medical Officer Yehia Hashad, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. A live webcast of the presentation will be available on the company's Investor Relations website.

Bausch + Lomb Corporation announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Chairman and CEO Brent Saunders, Executive Vice President and CFO Sam Eldessouky, and Chief Medical Officer Yehia Hashad, MD, will present on Monday, January 12, 2026. A live webcast of the presentation will be available on the company's Investor Relations website.

Bausch + Lomb Corporation has appointed Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. These appointments follow previous board changes in August 2025 and expand the board to 10 directors. The company's chairman and CEO, Brent Saunders, highlighted the extensive expertise of both new members, noting Dr. Alfonso's ophthalmology background and Collis's financial growth achievements as former CEO of Cencora, Inc.

Bausch + Lomb Corporation has received a consensus "Hold" rating from fifteen brokerages, with an average 12-month price target of $17.00. While the company recently beat EPS and revenue expectations, it still reports a negative net margin. Institutional interest is growing, with several hedge funds increasing their positions in BLCO.

A money manager at Carl Icahn’s firm, Steven Miller, is suing Bausch + Lomb and his employers, alleging discrimination based on race. Miller claims he was denied a board seat at Bausch + Lomb because the company required one of Icahn Capital's two board nominees to be "diverse," leading to a fellow money manager getting the position. He is seeking at least $221 million in damages, arguing the decision violates Title VII of the Civil Rights Act of 1964.